Extra trial to be conducted for KYNAPID in FDA special protocol agreement Cardiome Pharma Corp.

About KYNAPID KYNAPID Injection, or vernakalant , can be an investigational new medication for the rapid transformation of severe atrial fibrillation to sinus rhythm. Its system of action entails the selective blockade of multiple ion channels in the center that are known to be energetic during episodes of atrial fibrillation. In October 2003, Cardiome granted Astellas Pharma US, Inc. An exclusive license to develop and commercialize KYNAPID in THE UNITED STATES, with Astellas in charge of 75 percent of development costs. Astellas and Cardiome executed four successful Stage 3 scientific trials which demonstrated the prospect of KYNAPID as a conversion agent.Of the 2 2.2 million exposures managed by poison centers in 2013, about 50 percent had been pharmaceutical exposures, and almost all fatalities reported to poison centers had been due to the misuse and/or abuse of drugs and pharmaceuticals. In fact, 16 percent of pediatric ( The reinstatement of the National Prescription Drug Take-Back Times will enable Us citizens to properly dispose of their prescription drugs before children, the or visually impaired mentally, and pets have an opportunity to ingest potentially dangerous unused medications not designed for them. Information on the safe disposal of unused or undesirable over-the-counter medications is available here:..